Eli Lilly & CO
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to
Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with
Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
Volunteers needed for participation up to 104 weeks total. If you qualify and participate in the trial, there are no costs or insurance required by you for study related procedures and investigational products. Compensation for participation is provided for those who qualify and participate.
To Qualify, you must meet the following INCLUSION CRITERIA:
1.) 18 to 80 years of age.
2.) Diagnosis of UC for at least 3 months.
3.) Willing to have colonoscopy as a part of the qualification screening visit.
To Qualify, you must NOT meet the following EXCLUSION CRITERIA:
1.) Diagnosis of Crohn's Disease, IBD Unclassified or Primary Sclerosing Cholangitis.
2.) Have had (or will need) bowel resection (partial bowel removal).
3.) Female who is pregnant or breastfeeding.
ClinicalTrials.gov Identifier: NCT NCT05611671
https://clinicaltrials.gov/study/NCT05611671?term=NCT05611671&viewType=Card&rank=1

Eli Lilly UC Ulcerative Colitis Study Website Poster
We love our patients, so feel free to visit during normal business hours.
510 S Cowley Spokane, WA 99202
Mon | 09:00 am – 05:00 pm | |
Tue | 09:00 am – 05:00 pm | |
Wed | 09:00 am – 05:00 pm | |
Thu | 09:00 am – 05:00 pm | |
Fri | 09:00 am – 05:00 pm | |
Sat | Closed | |
Sun | Closed |
Copyright © 2026 Principle Research Solutions,llc - All Rights Reserved.
Your One-Stop Research SOLUTION
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.